1. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)
- Author
-
Zampetti, S., Campagna, G., Tiberti, C., Songini, M., Arpi, Ml., De Simone, G., Cossu, E., Cocco, L., Osborn, J., Bosi, E., Giorgino, F., Spoletini, M., Buzzetti, R., NIRAD Study Group, Adda, G, Di Lembo, S, Aglialoro, A, Cattaneo, A, Scassi, V, Anichini, R, Arcangeli, A, Arpi, Ml, Bardini, Rg, Basciano, P, Bracaccia, M, Pistoni, S, Bracaglia, D, Borzı, V, Emanuele, V 2nd, Cannata, F, Capitano, G, Cignarelli, M, Piemontese, S, Capuano, G, Carro, S, Cazzalini, C, Cocco, L, Ciccarone, Am, Cicioni, G, Cossu, E, Sano, F, Cucinotta, D, Di Benedetto, A, De Mattia, G, Mollica, Mr, De Cosmo, S, Minenna, A, Dei Cas, A, De Simone, G, Di Berardino, P, Dotta, F, Contini, V, Franzetti, I, Frontoni, S, Gadaleta, G, Galeone, G, Magiar, Av, Garofano, Mr, Gentile, S, Guarino, G, Giansanti, R, Genovese, S, Giancaterini, A, Leotta, S, Gianni, E, Burrafato, S, Giordano, C, Gigante, A, Cicalo, A, Giorgino, F, Gnasso, A, Fiaschi, E, Grossi, G, Deverardinis, F, Ianni, L, Iovine, C, Lauro, R, Federici, M, Spallone, V, Lo Presti, A, Scarpetta, Am, Lunari, R, Manna, R, Margotta, A, Mantovani, E, Matteoli, Mc, Matteucci, E, Chiesi, F, Maran, A, Mascetti, P, Quintana, T, Mazzucca, P, Melga, P, Cordera, R, Meloncelli, I, Morano, S, Morviducci, L, Nannipieri, M, Parillo, M, Pacifico, A, Pascal, G, Papini, E, Graziano, F, Passaro, A, Pata, P, Pontiroli, Ae, Pozzilli, P, Cipolloni, L, Guglielmi, C, Puccio, L, Raffa, Lm, Richini, D, Romano, R, Rotella, C, Santantonio, G, Sbriglia, Ms, Songini, M, Cau, V, Scorsone, A, Taboga, C, Tatti, P, Turco, A, Trovati, M, Fiori, E, Vasta, M, Vitale, F, Zavaroni, D, Buzzetti, R, Bosi, E, Giaccari, A, Di Pietro, S, Suraci, C, Locatelli, M, Bazzigaluppi, E, Falorni, A, Tiberti, C, Capizzi, M, Marandola, L, and Petrone, A.
- Subjects
Male ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Type 2 diabetes ,Logistic regression ,LADA ,Settore MED/13 - Endocrinologia ,Endocrinology ,Insulin ,Glutamate Decarboxylase ,Medicine (all) ,Diabete di tipo 1, autoanticorpi, GADA, LADA ,Titrimetry ,General Medicine ,Middle Aged ,Diabetes and Metabolism ,Titer ,Female ,Type 2 ,Type 1 ,Adult ,Risk ,medicine.medical_specialty ,medicine.drug_class ,autoanticorpi ,Socio-culturale ,GADA ,Diabete di tipo 1 ,Internal medicine ,Diabetes mellitus ,Diabetes Mellitus ,medicine ,Humans ,Hypoglycemic Agents ,Aged ,Autoantibodies ,Case-Control Studies ,Diabetes Mellitus, Type 1 ,Diabetes Mellitus, Type 2 ,Follow-Up Studies ,business.industry ,Autoantibody ,Case-control study ,medicine.disease ,Sulfonylurea ,business - Abstract
ObjectiveThe aim of this study was to determine whether glutamic acid decarboxylase antibody (GADA) titer and other clinical parameters could define the risk of progression to insulin therapy in latent autoimmune diabetes in adults (LADA) patients during a 7-year follow-up.MethodsThis study involved 220 LADA and 430 type 2 diabetes subjects followed up for 7 years from the time of GADA screening to evaluate their progression toward insulin therapy. Kaplan–Meier curves and multivariate logistic regression analysis were performed to identify the markers capable of influencing this progression.ResultsDuring the follow-up, the drop out was 4% in both groups. A total of 119 (56.1%) out of 212 LADA patients required insulin during the 7 years of follow-up. The Kaplan–Meier plots showed that 74/104 (71.1%) of high GADA titer required insulin compared with 45/108 (41.6%) of low GADA titer and with 86/412 (20.9%) of type 2 diabetes (P2and IA-2ICand zinc transporter 8 (ZnT8) positivity were also shown as the markers of faster progression (PPPConclusionsHigh GADA titer, BMI ≤ 25, ZnT8 and IA-2ICpositivity and sulfonylurea treatment, in the first year from diagnosis, significantly increase the progression toward insulin requirement in LADA patients.
- Published
- 2014
- Full Text
- View/download PDF